- Peroxidase-mediated ellipticine-DNA adduct formation explains the selective efficiency of this anticancer drug against breast cancer and leukemia2003 | Faculty of Science
- Peroxidase-mediated ellipticine-DNA adduct formation explains the selective efficiency of this anticancer drug against breast cancer and leukemia2003 | First Faculty of Medicine, Faculty of Mathematics and Physics
- Peroxidase and CYP-mediated ellipticine-DNA adduct formation explains the selective efficiency of this anticancer drug against breast cancer and leukemia2003 | Faculty of Science
- Peroxidase and CYP-mediated ellipticine-DNA adduct formation explains the selective efficiency of this anticancer drug against breast cancer and leukemia2003 | First Faculty of Medicine, Faculty of Mathematics and Physics
- Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b52012 | Faculty of Science
- The Hepatic Reductase Null (HRN (TM)) and Reductase Conditional Null (RCN) mouse models as suitable tools to study metabolism, toxicity and carcinogenicity of environmental pollutants2015 | Faculty of Science
- Application of hepatic cytochrome b(5)/P450 reductase null (HBRN) mice to study the role of cytochrome b(5) in the cytochrome P450-mediated bioactivation of the anticancer drug ellipticine2019 | Faculty of Science
- Cytochrome b(5) shifts oxidation of the anticancer drug ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation, thereby modulating its pharmacological efficacy2011 | Faculty of Science
- Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma2011 | Second Faculty of Medicine